Leaflet RALTEGRAVIR VIATRIS 600mg film-coated tablets

Product code:
W71328001
Quantity:
60
Indicated for:
HIV-1 infection
Route of administration:
oral
Substance:
raltegravir (integrase inhibitor)
ATC
J05AJ01 — Antiinfectives for systemic use | Direct acting antivirals | Integrase inhibitors

Precautions:

Breastfeeding warning

Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning

Pregnancy warning

Use during pregnancy only on medical advice.

Raltegravir is a medication used for the treatment of human immunodeficiency virus (HIV) infection. It is an integrase inhibitor that prevents the integration of viral DNA into the host cell genome, thereby reducing viral replication.

The medication is taken orally, usually in tablet form, and should be used in combination with other antiretroviral drugs as directed by your doctor. It is important to adhere to the treatment regimen to prevent the development of viral resistance.

Side effects may include nausea, fatigue, headache, or insomnia. In rare cases, severe adverse effects such as allergic reactions or liver function impairment may occur, requiring immediate medical attention.

Patients should inform their doctor about any other medications being used or pre-existing conditions, such as liver diseases, to ensure the safe use of raltegravir.

General data about RALTEGRAVIR VIATRIS 600mg

Substance:
raltegravir
Date of latest medicines list:
01-10-2025
Product code:
W71328001
Concentration:
600mg
Pharmaceutical form:
film-coated tablets
Quantity:
60
Product type:
Generic medicine
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
MYLAN HUNGARY KFT - UNGARIA
Holder:
VIATRIS LIMITED - IRLANDA
Number:
16195/2025/01
Shelf life:
18 months

Pharmaceutical forms available for raltegravir

Concentrations available for raltegravir

  • 100mg
  • 400mg
  • 600mg